The litigation is related to high-frequency spinal cord stimulation technology for pain relief.
Boston Scientific will pay Nevro $85 million, and in return, will receive a license to practice paresthesia-free therapy at frequencies below 1,500Hz, according to an Aug. 1 press release.
Boston Scientific will also give Nevro a license to use features from its family of patents.
This settlement concludes all ongoing litigation between the two parties.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
